(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the effect of anemia correction with NeoRecormon on cardiac structure
and function in patients with early diabetic nephropathy. The anticipated time on study
treatment is 1-2 years and the target sample size is 100-500 individuals.